Keywords: aspreva, cellcept, misses, endpoints, ph, iii, mg
Aspreva's CellCept misses endpoints in Ph III MG trial
Article | 06 November 2006
Canada's Aspreva Pharmaceuticals says CellCept (mycophenolate mofetil) yielded disappointing results in a myasthenia gravis trial. The Phase III randomized, double-blind, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
